1. Australia Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Oakridge Internatinal Ltd

Oakridge Internatinal Ltd

AASX:OAK
0.08
AUD
0.00
(0.00%)
0.00EPS
1.73MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
Revenue per Share
- -
- -
- -
- -
0.26
0.13
0.22
0.1
0.08
0.03
0.06
0.05
0.08
Basic EPS, GAAP
-10.15
-0.54
-1.37
-0.59
-1.51
-0.87
-0.37
-0.01
0.05
-0.03
-0.01
-0.04
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
4.33
2.46
1.07
1.1
1.11
0.38
-0.04
-0.02
0.11
0.08
0.07
0.04
0.03
Tangible Book Value per Share
4.33
2.46
1.07
1.1
0.64
0.37
-0.04
-0.02
0.11
0.08
0.07
0.04
0.03
Basic Weighted Avg Shares
- -
2
2
5
7
10
10
11
12
17
17
18
27
Sales/Revenue/Turnover
- -
- -
- -
- -
2
1
2
1
1
- -
1
1
2
Operating Margin (%)
- -
- -
- -
-9,290.84
-442.17
-611.02
-167.09
-165.47
-55.69
-165.75
-55.22
-123.62
-29.17
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-4
-1
-3
-3
-11
-8
-4
- -
1
-1
- -
-1
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
-11,835.07
-569.29
-658.02
-170.58
-12.19
66.36
-106.88
-10.58
-93.44
-5.77
Working Capital
- -
1
- -
9
5
3
2
- -
2
1
1
1
1
LT Debt
- -
- -
- -
1
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
4
4
3
10
9
4
- -
- -
2
1
1
1
1
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
-54.83
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
50.09
- -
- -
- -
- -
Return on Common Equity (%)
-85.68
-23.1
-80.65
-46.4
-116.04
-136.62
- -
- -
- -
-32.13
-9.02
-67.34
-13.32

Capital Structure

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

AUD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-88.87%
-181.48%
-12.49%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
-26.51%
-69.6%
-83.08%
Sales/Revenue/Turnover
- -
41.4%
173.74%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
1
2024
- -
- -
1
2025
- -
- -
2

Semi-annual Earnings Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-0.01
2024
- -
- -
-0.04
2025
- -
- -
- -

Semi-annual Dividends Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Con Unerkov
Full Time Employees
- -
Sector
Health technology
Industry
Medical specialties
Address
89 Pirie Street Adelaide SA Australia 5000
IPO Date
May 2, 2007
Website
oakridgeint.com
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Oakridge International Limited is an Australian technology company specializing in innovative healthcare technology solutions and Internet of Things (IoT) applications. The company develops and distributes proprietary nurse call and assistive technology hardware and software designed for use across multiple healthcare sectors including hospitals, aged care, disability care, and supported independent living facilities. Its core product portfolio includes ADRC (Auto Discovery Remote Control) technology, ADRC Shields, Umbo, Equinox, and UltarPlug, enabling smartphone users to connect and control electronic devices. Besides healthcare technology, Oakridge operates across segments including technology development, healthcare technology solutions, geothermal projects, and corporate activities primarily within Australia. Founded in 2006 and headquartered in Adelaide, Australia, Oakridge International Limited changed its name from Xped Limited in April 2021. Recently, the company has expanded its authorized partner network to increase market reach and sales pipelines, reporting a more than 100% increase in revenue from ordinary activities in 2025. Oakridge also maintains a strong pipeline of contracted orders and ongoing projects supported by strategic partner relationships. The company’s subsidiary, JCT Healthcare Technology, underscores its focus on innovative healthcare technology solutions. Oakridge continues to bolster its national presence and strengthen growth through partnerships and operational expansions within the Australian market. Its comprehensive product offering combined with strategic business development initiatives demonstrates the company’s commitment to advancing healthcare technology integration and IoT applications in healthcare settings.